Cancer Research Study
|
Stem Cell Transplant for Treatment of Metastatic Renal Cell (Kidney) Cancer
|
If you have been diagnosed with metastatic renal cell (kidney) cancer, you may be eligible for a stem cell transplant procedure here at the National Institutes of Health (NIH). Under evaluation is whether graft-versus-tumor effects can be generated against renal cell tumors. You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Cancer Research Study
|
Stem Cell Transplant for Treatment of Refractory Metastatic Cancers
|
Transplantation of cells from the bone marrow (called stem cells)that form blood cells and platelets is capable of curing patients with blood cancers such as acute and chronic leukemias. Powerful effects against cancer may be generated by specialized white blood cells from the donor, a process which is called graft-vs-leukemia or graft-vs-tumor. Recently, a similar graft-vs-solid tumor effect was demonstrated to occur in some patients with metastatic kidney cancer undergoing stem cell transplantation. This protocol is designed to test whether graft-vs-tumor effects can be generated against other types of solid tumors which have become resistant to standard therapy. Patients who have the following metastatic cancers: breast, bile ducts, small intestine, colon, rectal, esophageal, gastric, liver, pancreatic, prostate, or sarcomas, who have failed all standard treatment options and who have an HLA tissue-matched sibling or related family donor may be eligible for study enrollment. HLA typing can be performed for free on eligible patients and their family members by having blood samples mailed to the NIH.
The patient will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from their donor. The procedure will replace the patients immune system with the immune system of the healthy donor.
Patients on this study live in the area for approximately four months. We pay for all medical costs related to the transplant, but the patient is responsible for living expenses while here. We provide an allowance to help with living expenses while the patient is here on study.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute